Abstract:Primary hypertrophic osteoarthropathy (PHO) is a rare inherited disease caused by genetic defects in the prostaglandin metabolism pathway; disturbed prostaglandin E2 (PGE2 ) catabolism resulting in increased PGE2 level is suggested in the pathogenesis. Forty-three Han Chinese patients with PHO were studied and 41 of them were treated. Mutations in the HPGD gene, causing hypertrophic osteoarthropathy, primary, autosomal recessive 1 (PHOAR1; OMIM 259100), were identified in seven patients, and mutations in the SLCO2A1 gene, causing hypertrophic osteoarthropathy, primary, autosomal recessive 2 (PHOAR2; OMIM 614441), were identified in 36 patients. Clinical phenotypes of PHO varied, ranging from mild isolated finger clubbing to severe pachydermia and disabling joint swelling, even within families. Circulating PGE2 metabolism features of PHOAR2 were different from those of PHOAR1. Different frequency and severity of pachydermia between the subgroups were also indicated. A percentage of PHOAR2 patients suffered from gastrointestinal hemorrhage, but this symptom was not observed in the PHOAR1 subgroup. Clinical evidence highlighted the essential role of sex hormones in prostaglandin transporter regulation with respect to PHOAR2 onset, although no significant associations of urinary PGE2 or PGE-M with sex hormones were identified. Treatment with etoricoxib, a selective cyclooxygenase-2 inhibitor, was proved to be beneficial and safe. We detected its notable efficacy in decreasing urinary PGE2 levels in the majority of the enrolled patients during 6 months of intervention; clinical phenotypes assessed, including pachydermia, finger clubbing, and joint swelling, were improved. We found no visible evidence of a positive effect of etoricoxib on periostosis; however, significant links between urinary PGE2 and serum bone turnover markers indicated a potential role of decreased PGE2 in periostosis management. This is the largest reported cohort of subjects genetically diagnosed with PHO. For the first time, we systematically investigated the biochemical and clinical differences between PHOAR1 and PHOAR2, and prospectively showed the positive efficacy and safety of etoricoxib for PHO patients. © 2017 American Society for Bone and Mineral Research.

Targeted Exome Sequencing Identified a Novel Mutation Hotspot and a Deletion in Chinese Primary Hypertrophic Osteoarthropathy Patients.

Identification of Two Novel Mutations in the Slco2a1 Prostaglandin Transporter Gene in A Chinese Patient with Primary Hypertrophic Osteoarthropathy

Three Novel Mutations in the SLCO2A1 Gene in Two Chinese Families with Primary Hypertrophic Osteoarthropathy.

A novel mutation in the SLCO2A1 gene in a Chinese family with primary hypertrophic osteoarthropathy.

Clinical and Biochemical Characteristics of 12 Chinese Primary Hypertrophic Osteoarthropathy Patients with HPGD Mutations.

Two Novel Mutations in the SLCO2A1 Gene in a Chinese Patient with Primary Hypertrophic Osteoarthropathy.

[Genetic analysis of a child with Primary hypertrophic osteoarthropathy]

Exome Sequencing Identifies Slco2a1 Mutations As A Cause of Primary Hypertrophic Osteoarthropathy

Characterization of Mineral and Bone Metabolism Biomarkers in a Chinese Consanguineous Twin Family with Primary Hypertrophic Osteoarthropathy.

Case report: Novel homozygous HPGD variant leads to primary hypertrophic osteoarthropathy with intussusception and acro-osteolysis in a Chinese family

Mutations in Theslco2a1gene and Primary Hypertrophic Osteoarthropathy: A Clinical and Biochemical Characterization

Novel SLCO2A1compound Heterozygous Mutation Causing Primary Hypertrophic Osteoarthropathy with Bartter-like Hypokalemia in a Chinese Family

Monoallelic mutations in <i>SLCO2A1</i> cause autosomal dominant primary hypertrophic osteoarthropathy

[Genetic Diagnosis for a Chinese Han Family with Primary Hypertrophic Osteoarthropathy].

Novel SLCO2A1 Mutations Cause Gender-Differentiated Pachydermoperiostosis

Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families with Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results from a Six-Month Prospective Clinical Intervention.

Primary Hypertrophic Osteoarthropathy: Genetics, Clinical Features and Management

Identification of Two Novel Mutations in the PHEX Gene in Chinese Patients with Hypophosphatemic Rickets/Osteomalacia

Mutation Hot Spot Region in the HOGA1 Gene Associated with Primary Hyperoxaluria Type 3 in the Chinese Population.

Identification of 11 Potentially Relevant Gene Mutations Involved in Growth Retardation, Intellectual Disability, Joint Contracture, and Hepatopathy

Updated Genetic Testing of Primary Hyperoxaluria Type 1 in a Chinese Population: Results from a Single Center Study and a Systematic Review